A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to determine the efficacy following treatment with Aplidin® 5 mg/m2,
given as a 3 hours intravenous infusion every 2 weeks, in patients with relapsed or
refractory multiple myeloma (MM).